Gout in the transplant patient

Area of Science:

• Nephrology
• Rheumatology
• Immunology

Background:

• Organ transplantation necessitates immunosuppressive therapy, often involving cyclosporine.
• Cyclosporine is associated with adverse effects, including metabolic and rheumatologic complications.
• Hyperuricemia and gout are recognized risks in patients receiving cyclosporine.

Purpose of the Study:

• To highlight the risk of hyperuricemia and tophaceous gout in organ transplant recipients treated with cyclosporine.
• To emphasize the potential for rapid onset of these conditions.
• To inform treatment strategies for gouty arthritis in this patient population.

Main Methods:

• Observational analysis of patient data.
• Review of clinical presentations and laboratory findings.
• Assessment of treatment challenges and considerations.

Main Results:

• Patients on cyclosporine are at high risk for developing hyperuricemia and tophaceous gout.
• Gout symptoms can manifest shortly after initiating cyclosporine therapy.
• The severity of gout can be accelerated in these patients.

Conclusions:

• Cyclosporine-induced hyperuricemia and gout require prompt recognition and management.
• Treatment decisions must account for potential drug interactions.
• Allograft function and renal insufficiency are critical factors in managing gout in transplant patients.